Optimal Pharmacologic Treatment of ADPKD: What You Need to Know
December 17, 2021
June 17, 2022
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Medical Education Resources and CMEology.
This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.
- Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)™
- Nurses — 1.5 Nursing Contact Hours
- Pharmacists — 1.5 contact hours
All other health care professionals completing this course will be issued a statement of participation.
The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.
This activity consists of three related modules on the pharmacologic management of patients with ADPKD. The modules follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In this 1.5 hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of case studies with text, faculty and patient videos, and evidence-based animated slides. The activity is interactive, and the learner can advance through the material at their desired pace.
The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. The goal of this educational activity is to assist health care providers in the identification of patients at high risk of ADPKD progression when considering therapy and how to manage patients receiving disease-modifying therapy.
Upon completion of this activity, participants should be better able to:
- Apply evidence-based principles to select patients with ADPKD who are appropriate for disease-modifying therapy
- Describe the optimal use of REMS programs to improve safety and patient outcomes
- Employ strategies to mitigate risk when initiating and monitoring pharmacologic therapy for ADPKD
Neera Dahl, MD, PhD (Activity Chairperson)
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut
Gary Israel, MD
Section Chief: Abdomen
Professor of Radiology
Yale University School of Medicine
New Haven, Connecticut
Lena DeVietro, PharmD
Multi-Specialty Clinical Pharmacist
Yale New Haven Hospital
New Haven, Connecticut
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Physician Credit Designation
Medical Education Resources designates this activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit Designation
This CE activity provides 1.5 contact hour of continuing nursing education.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.
Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.5 contact hours (1.05 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Program Number - JA0003680-9999-21-231-H01-P)
This activity is certified as Knowledge-based CPE.
The record of your participation in this CE activity will be uploaded to the CPE Monitor under your NABP e-profile within 60 days.
You may print an individual statement of credit for this activity from your NABP e-profile.
Disclosures of Conflicts of Interest
Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
- Neera Dahl, MD, PhD (Activity Chairperson)
- Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.
- Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.
Gary Israel, MD has no relationships to disclose.
Lena DeVietro, PharmD has no relationships to disclose.
CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.
Instructions for Participation and CreditThere are no fees for participating in and receiving credit for this activity. During the period December 17, 2021 through June 17, 2022, participants must:
- Read the learning objectives and faculty disclosures.
- Study the educational activity.
- Complete the posttest by recording the best answer to each question.
- Complete the evaluation form.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.